From November 11 to 14, 2024, MEDICA 2024 – the leading international trade fair for medical technology, regarded as a key indicator of innovation in the medical device sector – was grandly held in Düsseldorf. The prestigious event brought together thousands of exhibiting companies from more than 140 countries and regions across the globe, and drew over 80,000 visitors from all over the world. Attendees gathered to witness and exchange cutting-edge medical technologies and innovative achievements, explore industry development trends, and share valuable professional experience.
As a provider of rapid sepsis diagnostic solutions, and driven by the vision to ensure equal access to high-quality healthcare for every corner of the world, Pilot Gene takes a global perspective and is committed to delivering competitive products and sepsis diagnostic solutions worldwide.
At MEDICA 2024, Pilot Gene showcased its rapid sepsis diagnostic solutions built on its proprietary, CE-IVD certified digital PCR platforms: the AD3207 and Pilot1200. The exhibits attracted numerous overseas customers who stopped by for in-depth discussions and consultations.
Compared with the limitations of traditional microbial culture and other molecular detection methods, Pilot Gene's digital PCR-based rapid sepsis diagnostic solution effectively shortens the detection turnaround time to 2 hours, raises pathogen detection rate by more than 30%, and significantly improves the quality of patient prognostic management.
It became a shared consensus among the many interested distributors consulting at the booth that innovation drives growth, and practice creates value.
Guided by the mission "Advancing Genetic Technology, Safeguarding Life and Health", Pilot Gene remains dedicated to providing users with accurate, efficient and convenient rapid sepsis diagnostic solutions. The company strives to offer more high-quality products and services to medical institutions at all levels, and jointly build a new high-quality healthcare ecosystem with global peers in the IVD industry.
